The first clinical trial of its kind found the weekly semaglutide jab cuts the amount people drink in one day by 40 per cent ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Another weight-loss jab will hit pharmacy shelves in Ireland at the end of next month – but it will only be available on ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

WEIGHT-loss jabs are taking the world by storm, with a staggering half a million of us now using them. The injections have ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Achieving and maintaining a healthy weight is beneficial for a number of reasons. A healthy weight lowers a person’s chance ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Let's take a closer look at each of these medications. Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient ...